AmerisourceBergen (ABC) Presents Long-term Vision and Guidance at Investor Day

AmerisourceBergen Corporation (NYSE: ABC) today hosted an investor day event in New York City. Steven H. Collis, Chairman, President & Chief Executive Officer; James F. Cleary, EVP & Chief Financial Officer; Bob Mauch, EVP & Group President; and Susan Lorenz-Fisher, SVP, Corporate Responsibility & Sustainability, discussed the company’s purpose, strategic imperatives, ESG commitments, and long-term financial growth outlook.

“As a global healthcare solutions leader with a foundation in pharmaceutical distribution that is complemented by higher-margin, high-growth services in key markets, AmerisourceBergen supports pharmaceutical innovation and access both upstream and downstream across our global footprint for our customers big and small,” said Steven H. Collis, Chairman, President & Chief Executive Officer. “We are proud to be the partner of choice to manufacturers and providers throughout the global pharmaceutical supply chain, allowing us to drive sustainable, long-term growth as we focus on enhancing our manufacturer services and advancing innovation to facilitate the future of healthcare. Our success is powered by our 42,000 purpose-driven team members who work tirelessly to execute on our important work – being united in our responsibility to create healthier futures.”

At the event, management detailed its five strategic imperatives, which will advance AmerisourceBergen’s vision of delivering long-term sustainable growth by maintaining a leading share of pharmaceutical distribution and best-in-class efficiency while growing the company’s complementary higher-margin and high-growth businesses in both its U.S. and international segments. The five strategic imperatives are:

• Lead with market leaders: fortifying long-term, strategic partnerships with key anchor customers;
• Leverage infrastructure to increase efficiency and to support customers in meeting consumer needs: using our scale and capabilities to better serve customers and increase the efficiency of the global pharmaceutical supply chain;
• Expand on leadership in specialty: building on AmerisourceBergen’s position to capture the opportunities created as pharmaceutical innovation continues to advance;
• Contribute to pharmaceutical outcomes: working collaboratively with partners up- and down-stream to facilitate positive health access and outcomes for patients; and
• Invest in innovation to further drive differentiation: supporting the continuously evolving healthcare landscape by providing leading solutions for customers.

AmerisourceBergen’s investments in talent and culture support its five strategic imperatives and are key to its commitments to live its purpose of creating healthier futures and positively impacting communities around the world.

The Company reminded investors that its fiscal year 2022 adjusted diluted earnings per share guidance of $10.80 to $11.05 includes:

• $0.70 of adjusted EPS contribution from Covid product sales, which include:
  • $0.60 of contribution in the U.S. Healthcare Solutions segment, and
  • $0.10 of contribution in the International Healthcare Solutions segment.
• This brings the baseline adjusted EPS for long-term growth to a range of $10.10 to $10.35.

As the Company executes on its strategic imperatives and benefits from its growth drivers over the long term, it expects:

• Adjusted operating income growth in the range of 5-8%;
  • U.S. Healthcare Solutions adjusted operating income growth in the range of 5-8%;
  • International Healthcare Solutions adjusted operating income growth in the range of 5-8%;
• Capital deployment growth in the range of 3-4%; and
• Adjusted Diluted Earnings Per Share growth in the range of 8-12%.

“AmerisourceBergen’s strong financial position and solid base of growth drivers position us well to deliver on our long-term financial targets, including a double-digit compound annual growth rate for adjusted EPS at the midpoint of our range,” said James F. Cleary, EVP & Chief Financial Officer. “Our business model generates sustainable and growing free cash flow, and this long-range plan includes a strengthening balance sheet, improving credit metrics, and increasing firepower for further potential share repurchases and strategic M&A opportunities.”

The Company’s fiscal year 2022 guidance does not include any potential benefit from the $1 billion share repurchase authorization.

Investor Day Replay

Please check the website investor.amerisourcebergen.com to access the event replay and presentation.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Sanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy
• West Pharma (WST) Tops Q1 EPS by 26c, provides guidance